Original Article | 更新时间:2024-03-22
    • Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway

    • Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway

    • JI Hua-feng

      ,  

      YANG Zi-qiang

      ,  

      HAN Jun-jun

      ,  

      LI He-fang

      ,  

      JIN Zhao-qing

      ,  

      CHEN Wei-qing

      ,  

      CHEN Fei-hua

      ,  

      GONG Mou-chun

      ,  
    • 中国结合医学杂志(英文版)   2024年30卷第4期 页码:339-347
    • DOI:10.1007/s11655-023-3705-1    

      中图分类号:
    • 纸质出版日期:2024-04-01

      网络出版日期:2023-11-09

      录用日期:2023-03-14

    扫 描 看 全 文

  • 引用本文

  • Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway[J]. 中国结合医学杂志(英文版), 2024,30(4):339-347. DOI: 10.1007/s11655-023-3705-1.

    JI Hua-feng, YANG Zi-qiang, HAN Jun-jun, et al. Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway[J]. Chinese Journal of Integrative Medicine, 2024,30(4):339-347. DOI: 10.1007/s11655-023-3705-1.

  •  
  •  
    论文导航

    Abstract

    Objective:

    To explore the anti-tumor effect of safflower yellow (SY) against hepatocellular carcinoma (HCC) and the underlying potential mechanism.

    Methods:

    An in vitro model was established by mixing Luc-Hepa1-6 cells and CD3+CD8+ T cells, followed by adding programmed cell death protein 1 (PD-1) antibody (Anti-mPD-1) with or without SY. The apoptosis was detected by flow cytometry and the level of inflammatory cytokines was determined by enzyme-linked immunosorbent assay. The protein levels of programmed cell death 1 ligand 1 (PD-L1), chemokine ligand (CCL5), C-X-C motif chemokine ligand 10 (CXCL10) were measured by Western blot. An in situ animal model was established in mice followed by treatment with anti-mPD-1 with or without SY. Bioluminescence imaging was monitored with an AniView 100 imaging system. To establish the FAK-overexpressed Luc-Hepa1-6 cells, cells were transfected with adenovirus containing pcDNA3.1-FAK for 48 h.

    Results:

    The fluorescence intensity, apoptotic rate, release of inflammatory cytokines, and CCL5/CXCL10 secretion were dramatically facilitated by anti-mPD-1 (P <0.01), accompanied by an inactivation of PD-1/PD-L1 axis, which were extremely further enhanced by SY (P <0.05 or P <0.01). Increased fluorescence intensity, elevated percentage of CD3+CD8+ T cells, facilitated release of inflammatory cytokines, inactivated PD-1/PD-L1 axis, and increased CCL5/CXCL10 secretion were observed in Anti-mPD-1 treated mice (P <0.01), which were markedly enhanced by SY (P <0.05 or P <0.01). Furthermore, the enhanced effects of SY on inhibiting tumor cell growth, facilitating apoptosis and inflammatory cytokine releasing, suppressing the PD-1/PD-L1 axis, and inducing the CCL5/CXCL10 secretion in Anti-mPD-1 treated mixture of Luc-Hepa1-6 cells and CD3+CD8+ T cells were abolished by FAK overexpression (P <0.01).

    Conclusion:

    SY inhibited the progression of HCC by mediating immunological tolerance through inhibiting FAK.

    Keywords

    hepatocellular carcinoma; safflower yellow; Chinese medicine; tumor microenvironment; programmed cell death protein 1; focal adhesion kinase

    更多指标>

    0

    浏览量

    0

    下载量

    0

    CSCD

    文章被引用时,请邮件提醒。
    提交
    工具集
    下载
    参考文献导出
    分享
    收藏
    添加至我的专辑

    相关文章

    Immunoregulatory and Anti-cancer Activities of Combination Treatment of Novel Four-Herb Formula and Doxorubicin in 4T1-Breast Cancer Bearing Mice
    Data Mining and Systems Pharmacology to Elucidate Effectiveness and Mechanisms of Chinese Medicine in Treating Primary Liver Cancer
    Mechanism of Fuzheng Kang'ai Formula Regulating Tumor Microenvironment in Non-Small Cell Lung Cancer
    Bear Bile Powder Inhibits Growth of Hepatocellular Carcinoma via Suppressing STAT3 Signaling Pathway in Mice
    Chemical Composition, Pharmacological Effects and Clinical Applications of Cinobufacini

    相关作者

    暂无数据

    相关机构

    Institute of Chinese Medicine, The Chinese University of Hong Kong
    State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong
    Department of Chemical Pathology, The Chinese University of Hong Kong
    Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, STEM College, RMIT University
    Li Dak Sum Yip Yio Chin R & D Centre for Chinese Medicine, The Chinese University of Hong Kong SAR
    0